Clover Health Investments, Corp. (NASDAQ:CLOV – Get Free Report) VP Joseph Frank Oldakowski sold 20,000 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $5.16, for a total value of $103,200.00. Following the transaction, the vice president directly owned 279,067 shares of the company’s stock, valued at approximately $1,439,985.72. The trade was a 6.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Joseph Frank Oldakowski also recently made the following trade(s):
- On Tuesday, June 16th, Joseph Frank Oldakowski sold 12,102 shares of Clover Health Investments stock. The stock was sold at an average price of $4.86, for a total transaction of $58,815.72.
Clover Health Investments Stock Up 5.8%
Clover Health Investments stock traded up $0.28 during mid-day trading on Monday, hitting $5.10. The company’s stock had a trading volume of 5,397,714 shares, compared to its average volume of 3,434,186. The stock has a market capitalization of $2.71 billion, a P/E ratio of -101.98 and a beta of 2.47. The stock’s fifty day moving average price is $4.43 and its two-hundred day moving average price is $3.55. Clover Health Investments, Corp. has a twelve month low of $1.58 and a twelve month high of $5.59.
Clover Health Investments (NASDAQ:CLOV – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. Clover Health Investments had a negative net margin of 0.74% and a negative return on equity of 4.20%. The firm had revenue of $743.17 million during the quarter, compared to analyst estimates of $728.27 million.
Hedge Funds Weigh In On Clover Health Investments
Several large investors have recently modified their holdings of the stock. California State Teachers Retirement System boosted its holdings in shares of Clover Health Investments by 387.2% during the 2nd quarter. California State Teachers Retirement System now owns 2,421,577 shares of the company’s stock worth $12,689,000 after buying an additional 1,924,571 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Clover Health Investments in the second quarter valued at about $6,346,000. Tidal Investments LLC acquired a new position in shares of Clover Health Investments in the second quarter valued at about $2,156,000. Turtle Creek Wealth Advisors LLC increased its position in Clover Health Investments by 29.4% during the first quarter. Turtle Creek Wealth Advisors LLC now owns 220,000 shares of the company’s stock worth $387,000 after acquiring an additional 50,000 shares during the period. Finally, Lazard Asset Management LLC bought a new position in Clover Health Investments during the first quarter worth about $309,000. 19.77% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts have issued reports on CLOV shares. Canaccord Genuity Group increased their target price on Clover Health Investments from $4.20 to $5.50 and gave the stock a “buy” rating in a report on Tuesday, July 21st. UBS Group lifted their price objective on shares of Clover Health Investments from $4.75 to $5.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clover Health Investments in a report on Wednesday, June 24th. Wall Street Zen downgraded Clover Health Investments from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Clover Health Investments in a research note on Thursday. They issued a “buy” rating and a $6.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.75.
Check Out Our Latest Report on CLOV
About Clover Health Investments
Clover Health Investments, Inc is a healthcare technology and insurance company focused on providing Medicare Advantage plans to eligible Medicare beneficiaries. Its insurance business offers medical coverage and related healthcare benefits through plans available in select counties across the United States.
The company also develops and uses Clover Assistant, a technology platform designed to support physicians with patient information, clinical insights, care recommendations and tools intended to help improve healthcare outcomes.
See Also
- Five stocks we like better than Clover Health Investments
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Clover Health Investments Right Now?
Before you consider Clover Health Investments, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Clover Health Investments wasn’t on the list.
While Clover Health Investments currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
